Industry Watch [to 18 October2014]
Selected media releases and other selected content from industry.
:: Shantha’s Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India
Hyderabad, India, – Oct 14, 2014 – Sanofi Pasteur, the vaccines division of Sanofi, announced
today the start of a phase III clinical trial in India for its investigational rotavirus vaccine, developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, India. The trial is designed to show non-inferiority against a currently licensed vaccine with the use of three, ready-to-use liquid doses administered orally, starting from six-to-eight weeks of age, with the subsequent doses administered at 4 weeks intervals. Close to 1,200 volunteers are being sought at 12 clinical trial sites in India. Shantha’s investigational rotavirus vaccine includes antigens against serotypes G1, G2, G3 and G4…
…“We aim to provide an affordable vaccine to meet the still significant medical need in emerging markets, like India, and through partnerships with organizations like Gavi, the Vaccine Alliance”, commented Olivier Charmeil, Sanofi Pasteur’s President & CEO. ” “Sanofi Pasteur wants to be in the position to target a major role in the growing rotavirus market in developing countries, with a key focus on the Gavi market, in public markets for non-Gavi countries, as well as private segments in emerging markets.”…
:: GSK – Indigenous and refugee programs win immunisation boost
14 Oct 2014 – GSK’s 2014 Immunisation Grants have been awarded to programs that are helping improve access and awareness of vaccination services for Indigenous and refugee communities. Winners are from across Australia and include medical groups in Mildura, Townsville, Geraldton and Brisbane. They each receive $20,000 for their program…
:: PhRMA: Statement on Appointment of “Ebola Czar”
October 17, 2014 Washington, DC – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today issued the following statement on the selection of Ron Klain to manage the U.S. government’s response to preventing the spread of the Ebola virus:
“Protecting patients and their families from the devastating effects of Ebola is a national priority. As Mr. Klain takes on the important and challenging role of coordinating the government’s response to the Ebola outbreak, our industry stands ready to support these efforts by using our resources and expertise to assist patients and their families affected.
“Stopping the spread of Ebola will require close collaboration and engagement from a wide range of stakeholders, including health care providers, relief organizations, government agencies, and biopharmaceutical companies. Over the past several years, researchers have been working to develop vaccines and treatments to prevent infection and fight its effects, and there are at least two Ebola vaccines currently in the biopharmaceutical pipeline. PhRMA members are also helping to expand capacity on the ground in West Africa to take care of affected patients, including donating medicines, providing funding to relief organizations for infrastructure improvements, medical products and protective equipment for health care workers, and donating funds for disease education and prevention efforts within the region.”